March 13th 2024
Treatment for relapsed or refractory diffuse large B-cell lymphoma with brentuximab vedotin, lenalidomide, and rituximab contributed to an improvement in overall survival vs lenalidomide/rituximab/placebo.
NX-5948 Gets FDA Fast Track Designation for Relapsed/Refractory CLL/SLL
January 18th 2024A fast track designation has been granted by the FDA to the novel BTK degrader, NX-5948, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.
Pirtobrutinib Generates Durable Responses in CLL/SLL After BTKi Therapy
December 11th 2023The use of pirtobrutinib following covalent Bruton tyrosine kinase inhibitor therapy may be an important sequencing approach in chronic lymphocytic leukemia/small lymphocytic lymphoma, according to recent research.
Adding Pembrolizumab to COPDAC-28 Consolidation May Augment Responses in Classical Hodgkin Lymphoma
September 4th 2023Patients with high-risk classical Hodgkin lymphoma who experience a slow early response to frontline chemotherapy may benefit from the addition of pembrolizumab to COPDAC-28 consolidation.
Liso-cel Demonstrates Rapid, Durable Responses in Patients with Relapsed/Refractory CLL/SLL
June 24th 2023The phase 1/2 TRANSCEND CLL 004 trial met its primary end point by demonstrating that lisocabtagene maraleucel elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Nivolumab Plus AVD Confers PFS Benefit for Treatment of Advanced-Stage Hodgkin Lymphoma
June 4th 2023Patients with advanced-stage Hodgkin lymphoma who received nivolumab plus AVD experienced a 1-year estimated progression-free survival rate of 94% meeting the primary end point of the phase 3 SWOG S1826 trial.